345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis

医学 湿疹面积及严重程度指数 安慰剂 斯科拉德 临床终点 内科学 随机对照试验 特应性皮炎 胃肠病学 免疫学 疾病 病理 皮肤科生活质量指数 替代医学
作者
Stephan Weidinger,Michael J. Cork,Adam Reich,Thomas Bieber,Sally Gilbert,Nuala Brennan,Rosamund Wilson,Davide Lucchesi,Natalie Rynkiewicz,Marisa Stebegg,Ben Porter‐Brown
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:188 (Supplement_2) 被引量:8
标识
DOI:10.1093/bjd/ljac140.039
摘要

Abstract OX40Ligand (OX40L) upregulation on antigen-presenting cells (APCs) following antigen presentation contributes to the survival and functional activation of T helper (Th) 2 and Th1/17/22 cells, which are central to the inflammation and pathological outcomes in atopic dermatitis (AD). In a Phase 2a trial (NCT03754309), amlitelimab, a fully human, non-depleting, non-cytotoxic anti-OX40L monoclonal antibody, was effective in treating patients with moderate-to-severe AD. To assess the effects of amlitelimab on interleukin (IL)-22, an important Th22-associated disease mediator of AD. 89 patients with moderate-to-severe AD were enrolled in a Phase 2a randomized, double-blind, placebo-controlled, multicentre trial and randomized 1 : 1 : 1 to intravenous amlitelimab low dose (200 mg loading/100 mg maintenance every 4 weeks [Q4W]; n = 29), high dose (500 mg/250 mg Q4W; n = 30) or placebo (Q4W; n = 29) until week 12. The primary efficacy endpoint was the percentage change in Eczema Area and Severity Index (EASI) from baseline to week 16. Other disease severity measurements included SCORing of Atopic Dermatitis (SCORAD) and validated Investigator Global Assessment (vIGA). Serum was collected at baseline, week 4 and week 16, and further collected at week 24 and week 36 in responders, defined as patients who reached vIGA 0/1 at week 16. IL-22 levels were determined by ultrasensitive single-molecule immunoassay (Simoa). Of 88 subjects who received study treatment, 59 were evaluable at week 16. Amlitelimab was well tolerated with an unremarkable safety profile. The mean percentage change in EASI from baseline at week 16 was −80.12% for amlitelimab low dose and −69.97% for amlitelimab high dose vs. −49.37% for placebo (nominal P-values: 0.009 [amlitelimab low dose vs. placebo] and 0.072 [amlitelimab high dose vs. placebo]). Amlitelimab-treated patients who achieved vIGA 0/1 at week 16 had sustained clinical responses up to week 36. No difference in IL-22 serum levels was found between groups at baseline. IL-22 levels correlated with disease severity at baseline, as measured by EASI and SCORAD (r = 0.53, P < 0.0001; and r = 0.36, P = 0.001; respectively). A significant reduction in IL-22 levels was observed at week 16 in amlitelimab-treated patients (low dose P < 0.0001; high dose P = 0.001), but not in the placebo group (P = 0.381). The amlitelimab-induced decrease in IL-22 levels was maintained until week 36 in those defined as vIGA 0/1 responders at week 16. OX40L blockade on APCs represents a promising novel approach in the treatment of AD by effectively targeting underlying T-cell immune dysregulation. Amlitelimab monotherapy not only provided a sustained and clinically meaningful improvement in disease activity compared with placebo in patients with moderate-to-severe AD, but also significantly decreased serum levels of IL-22, a Th22 cell-associated cytokine involved in the underlying immunopathogenesis of AD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cyndi完成签到,获得积分0
刚刚
1秒前
贰鸟应助七月流火采纳,获得10
2秒前
yulia完成签到 ,获得积分10
3秒前
佳期如梦完成签到 ,获得积分10
3秒前
4秒前
阿Q完成签到,获得积分10
5秒前
6秒前
彬琪发布了新的文献求助10
7秒前
7秒前
8秒前
8秒前
雨木目完成签到,获得积分10
9秒前
小鱼完成签到,获得积分10
9秒前
chenkaixin发布了新的文献求助10
9秒前
梦XING完成签到 ,获得积分10
10秒前
eternity136发布了新的文献求助10
10秒前
vv完成签到,获得积分10
11秒前
11秒前
哈哈哈哈发布了新的文献求助20
11秒前
KANG完成签到,获得积分10
12秒前
义气黄焖排骨完成签到,获得积分10
12秒前
13秒前
如梦如画发布了新的文献求助10
13秒前
Hannes应助15902933324sjc采纳,获得10
14秒前
14秒前
14秒前
梓默完成签到 ,获得积分10
14秒前
我是老大应助Japan采纳,获得10
15秒前
彬琪完成签到,获得积分10
15秒前
红尘踏歌完成签到,获得积分10
15秒前
不忘初心发布了新的文献求助10
16秒前
18746005898完成签到 ,获得积分10
16秒前
chenkaixin完成签到,获得积分10
17秒前
WangZhen完成签到,获得积分20
18秒前
乔木木完成签到,获得积分10
18秒前
一路畅通accept完成签到,获得积分10
18秒前
潇湘学术完成签到,获得积分10
18秒前
烂漫的如冬完成签到,获得积分10
19秒前
koi发布了新的文献求助10
19秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038619
求助须知:如何正确求助?哪些是违规求助? 3576294
关于积分的说明 11375058
捐赠科研通 3306084
什么是DOI,文献DOI怎么找? 1819374
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815066